Drug Trial Radar · NCT04630808
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
696
Actual
Start
Nov 9, 2020
Primary completion
Apr 11, 2025
Study completion Jun 25, 2025
Sponsor
- Lead sponsor
- Nicox Ophthalmics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
NCX 470 0.1%Drug
NCX 470 Ophthalmic Solution, 0.1%
Latanoprost 0.005%Drug
Latanoprost Ophthalmic Solution, 0.005%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline IOPTime frame: Up to 3 months
Locations
88 sites in 2 countries. Site status is shown where the registry gives one.
Nicox Clinical Site
Dothan, Alabama
Nicox Clinical Site
Chandler, Arizona
Nicox Clinical Site
Phoenix, Arizona
Nicox Clinical Site
Burbank, California
Nicox Clinical Site
Garden Grove, California
Nicox Clinical Site
Huntington Beach, California
Nicox Clinical Site
La Jolla, California
Nicox Clinical Site
Murrieta, California
Nicox Clinical Site
Newport Beach, California
Nicox Clinical Site
Pasadena, California
Nicox Clinical Site
Petaluma, California
Nicox Clinical Site
Redlands, California
Nicox Clinical Site
San Francisco, California
Nicox Clinical Site
Danbury, Connecticut
Nicox Clinical Site
Boynton Beach, Florida
Nicox Clinical Site
Delray Beach, Florida
Nicox Clinical Site
Fort Lauderdale, Florida
Nicox Clinical Site
Fort Myers, Florida
Nicox Clinical Site
Jacksonville, Florida
Nicox Clinical Site
Jupiter, Florida
Nicox Clinical Site
Lakeland, Florida
Nicox Clinical Site
Largo, Florida
Nicox Clinical Site
Mt. Dora, Florida
Nicox Clinical Site
Venice, Florida
Nicox Clinical Site
Morrow, Georgia
Nicox Clinical Site
Roswell, Georgia
Nicox Clinical Site
Peoria, Illinois
Nicox Clinical Site
Rock Island, Illinois
Nicox Clinical Site
Indianapolis, Indiana
Nicox Clinical Site
Bangor, Maine
Nicox Clinical Site
Boston, Massachusetts
Nicox Clinical Site
Lancaster, Massachusetts
Nicox Clinical Site
Grand Rapids, Michigan
Nicox Clinical Site
Chaska, Minnesota
Nicox Clinical Site
Kansas City, Missouri
Nicox Clinical Site
St Louis, Missouri
Nicox Clinical Site
Clifton Park, New York
Nicox Clinical Site
The Bronx, New York
Nicox Clinical Site
Troy, New York
Nicox Clinical Site
Asheville, North Carolina
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.